CRVO

+ Watchlist + Portfolio

CervoMed Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.71
52-Week Range: $2.13 – $10.89
Market Cap: $38.70M
P/E (TTM): —
EPS (TTM): -3.21
Dividend Yield: —

Advanced Metrics

Price/Book: 1.51
PEG Ratio: —
Return on Equity: -107.62%
Return on Assets: -60.80%
Gross Margin: 0.00%
Operating Margin: -9406.96%
Profit Margin: 0.00%
Current Ratio: 8.57
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-16.29M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $16.03M

CRVO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.34M	$8.44M	$18.80M	$21.82M
Selling, General & Admin	$2.14M	$6.52M	$9.17M	$10.48M
Operating Expenses	$3.48M	$7.81M	$18.23M	$28.29M
Operating Income	-$3.48M	-$7.81M	-$18.23M	-$28.29M
EBITDA	-$5.80M	-$7.81M	-$18.23M	-$28.29M
Pretax Income	-$5.80M	-$2.17M	-$16.29M	-$26.97M
Income Tax	$0.00	—	—	—
Net Income	-$5.80M	-$2.17M	-$16.29M	-$26.97M
Diluted EPS	-11.20	-0.82	-2.02	-2.98
Diluted Shares	518140	2.66M	8.07M	9.04M

CRVO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.09M	$7.79M	$9.00M	$8.24M
Receivables	$0.00	$915.40K	$2.25M	$426.99K
Current Assets	$4.16M	$9.96M	$43.08M	$22.88M
Total Assets	$4.16M	$9.97M	$43.08M	$22.88M
Current Liabilities	$13.16M	$2.60M	$3.88M	$4.66M
Total Debt	$12.41M	—	—	—
Total Liabilities	$37.44M	$2.60M	$3.88M	$4.66M
Retained Earnings	-$52.27M	-$54.44M	-$70.73M	-$97.70M
Shareholders' Equity	-$33.29M	$7.38M	$39.20M	$18.22M
Working Capital	-$9.00M	$7.37M	$39.20M	$18.22M
Net Debt	$8.32M	—	—	—

CRVO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$2.57M	-$7.45M	-$16.53M	-$23.45M
Free Cash Flow	-$2.57M	-$7.45M	-$16.53M	-$23.45M
Depreciation & Amortisation	$0.00	—	—	—
Stock-Based Compensation	$333.83K	$407.63K	$1.41M	$1.45M
Investing Cash Flow	-$12.24M	$0.00	-$28.66M	$18.10M
Financing Cash Flow	$0.00	$11.15M	$46.40M	$4.59M
Net Change in Cash	-$2.57M	$3.70M	$1.21M	-$764.03K

CRVO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$4.84M	$5.11M	$6.04M	$5.83M	$5.14M
Selling, General & Admin	$2.38M	$3.27M	$2.33M	$2.51M	$2.98M
Operating Expenses	$5.30M	$6.62M	$8.04M	$8.33M	$8.11M
Operating Income	-$5.30M	-$6.62M	-$8.04M	-$8.33M	-$8.11M
EBITDA	-$5.30M	-$6.62M	-$8.04M	-$8.33M	-$8.11M
Pretax Income	-$4.89M	-$6.26M	-$7.73M	-$8.09M	-$7.96M
Net Income	-$4.89M	-$6.26M	-$7.73M	-$8.09M	-$7.96M
Diluted EPS	-0.56	-0.84	-0.84	—	-0.86
Diluted Shares	8.70M	9.25M	9.25M	—	9.26M

CRVO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.50M	$8.32M	$9.44M	$8.24M	$7.94M
Receivables	$1.63M	$2.36M	$1.36M	$426.99K	$0.00
Current Assets	$38.58M	$38.08M	$30.61M	$22.88M	$15.11M
Total Assets	$38.58M	$38.08M	$30.61M	$22.88M	$15.11M
Current Liabilities	$3.94M	$4.64M	$4.60M	$4.66M	$4.50M
Total Liabilities	$3.94M	$4.64M	$4.60M	$4.66M	$4.50M
Retained Earnings	-$75.63M	-$81.88M	-$89.61M	-$97.70M	-$105.66M
Shareholders' Equity	$34.63M	$33.44M	$26.01M	$18.22M	$10.62M
Working Capital	$34.63M	$33.44M	$26.01M	$18.22M	$10.62M

CRVO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.89M	-$6.51M	-$6.47M	-$6.58M	-$8.02M
Free Cash Flow	-$3.89M	-$6.51M	-$6.47M	-$6.58M	-$8.02M
Stock-Based Compensation	$361.17K	$497.01K	$291.72K	$298.74K	$349.20K
Investing Cash Flow	$5.40M	-$254.99K	$7.58M	$5.37M	$7.71M
Financing Cash Flow	$0.00	$4.59M	$0.00	$0.00	$13.80K
Net Change in Cash	$1.50M	-$2.18M	$1.12M	-$1.20M	-$293.72K

Market Snapshot

About

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Headquartered in Rockville, Maryland, the company is advancing neflamapimod, a selective p38 alpha kinase inhibitor, as a potential therapy for dementia with Lewy bodies (DLB) and other neurological conditions. CervoMed's drug candidate targets neuroinflammation, a key factor in neurodegenerative disease progression. The company was formerly known as Cerevance and rebranded following its strategic focus on neflamapimod development.